Loading data for CABA — first visit, this takes a few seconds.

Alert

Cabaletta Bio Inc. (CABA)

NasdaqGS: CABA · Real-Time Price · USD

3.13

-0.06 (-1.88%)

At close: Aug 21, 2026, 8:00 PM

3.18

+1.60%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

-1.88% (1D)

No data available

Bid	2.36
Market Cap	530.68M
Revenue (ttm)	n/a
Net Income (ttm)	-181.32M
	3.25
	-1.38
	n/a
	-2.12
P/B (ttm)	2.49
P/S (ttm)	n/a
Earnings Date	Nov 16, 2026

Ask	3.14
Volume	4,296,031
Avg. Volume (20D)	4,665,327
Open	3.22
Previous Close	3.19
Day's Range	3.08 - 3.33
52-Week Range	1.40 - 4.23
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenil...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 25, 2019

Employees 154

Stock Exchange NasdaqGS

Ticker Symbol CABA

Website https://www.cabalettabio.com

Full Company Profile

Financial Performance

In 2025, Cabaletta Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -167.86M, an increase of 44.87%.

Financial Statements

Earnings Surprise

Cabaletta Bio has released their quarterly earnings on Aug 13, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.34 misses estimates by 0.00, with 53.42% YoY growth.

Next Earnings Release

Cabaletta Bio Inc. is scheduled to release its earnings on Nov 16, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 month ago · 24/7 Wall St.

Kyverna Therapeutics Sinks 13%: Here’s Why

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity...

2 months ago · Insider Monkey

How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup

Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 story is focused on rese-cel, an experimental cell therapy being developed for ...

2 months ago · Exec Edge

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b...

2 months ago · Insider Monkey

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases

Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data fro...

3 months ago · Zacks

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Page 1 of 2

Cabaletta Bio Inc. (CABA)